ATRCAtriCure, Inc.$61.51Citizens
RatingMarket Outperform unchanged
Price target$52 → $68 +30.8% · +$16
Price at note$57.67 (Oct 21 close) +17.9% upside (+$10.33) to the $68 target
Third-party analyst actions
Analyst moves
Upgrades, downgrades, new coverage and price-target changes from Wall Street firms on the stocks we cover. What each firm published, laid out plainly. These are third-party actions, not our views.
Showing every move on file for ATRCClear search
30 moves
ⓘ Rating colors
- Strong BuyConviction Buy, Top Pick, Top Pick Buy
- BuyLong Term Buy, Speculative Buy, Outright Buy
- OutperformOverweight, Accumulate, Moderate Buy, Positive
- HoldNeutral, Equal Weight, Market Perform, Sector Perform
- UnderperformUnderweight, Reduce, Moderate Sell, Negative
- Sell
- Strong Sell
- OtherRatings we can't place on the scale
Each firm's own wording is placed on one seven-step scale so ratings compare at a glance. ▲ / ▼ between two ratings marks an upgrade or a downgrade. The colours describe what the firm said; they are not our view.
Wednesday · Oct 21, 2026
ATRCAtriCure, Inc.$61.51Monday · Oct 12, 2026
ATRCAtriCure, Inc.$61.51BTIG
RatingBuy unchanged
Price target$55 → $63 +14.5% · +$8
Price at note$57.28 (Oct 12 close) +10.0% upside (+$5.72) to the $63 target
Friday · Oct 2, 2026
ATRCAtriCure, Inc.$61.51Freedom Capital Markets
RatingBuy▼Hold
Price target$43 → $57 +32.6% · +$14
Price at note$55.14 (Oct 2 close) +3.4% upside (+$1.86) to the $57 target
Wednesday · Sep 2, 2026
ATRCAtriCure, Inc.$61.51Needham
RatingBuy unchanged
Price target$45 → $64 +42.2% · +$19
Thursday · Aug 27, 2026
ATRCAtriCure, Inc.$61.51Piper Sandler
RatingOverweight unchanged
Price target$50 → $60 +20.0% · +$10
Monday · Aug 24, 2026
ATRCAtriCure, Inc.$61.51BTIG
RatingBuy unchanged
Price target$45 → $55 +22.2% · +$10
Tuesday · Jul 28, 2026
ATRCAtriCure, Inc.$61.51UBS
RatingBuy unchanged
Price target$55 → $50 −9.1% · −$5
Wednesday · May 6, 2026
ATRCAtriCure, Inc.$61.51Canaccord Genuity
RatingBuy unchanged
Price target$53 → $55 +3.8% · +$2
Wednesday · Feb 18, 2026
ATRCAtriCure, Inc.$61.51Canaccord Genuity
RatingBuy unchanged
Price target$64 → $53 −17.2% · −$11
ATRCAtriCure, Inc.$61.51UBS
RatingBuy unchanged
Price target$60 → $55 −8.3% · −$5
ATRCAtriCure, Inc.$61.51Citizens
RatingMarket Outperform unchanged
Price target$60 → $52 −13.3% · −$8
ATRCAtriCure, Inc.$61.51Oppenheimer
RatingOutperform▼Perform
ATRCAtriCure, Inc.$61.51BTIG
RatingBuy unchanged
Price target$54 unchanged
Thursday · Feb 12, 2026
ATRCAtriCure, Inc.$61.51Needham
RatingBuy unchanged
Price target$45 unchanged
Tuesday · Dec 16, 2025
ATRCAtriCure, Inc.$61.51JP Morgan
RatingOverweight unchanged
Price target$42 → $48 +14.3% · +$6
Thursday · Oct 30, 2025
ATRCAtriCure, Inc.$61.51Canaccord Genuity
RatingBuy unchanged
Price target$53 → $64 +20.8% · +$11
Wednesday · Jul 30, 2025
ATRCAtriCure, Inc.$61.51Needham
RatingBuy unchanged
Price target$44 → $45 +2.3% · +$1
Wednesday · Apr 30, 2025
ATRCAtriCure, Inc.$61.51BTIG
RatingBuy unchanged
Price target$58 → $52 −10.3% · −$6
ATRCAtriCure, Inc.$61.51UBS
RatingBuy unchanged
Price target$60 → $58 −3.3% · −$2
ATRCAtriCure, Inc.$61.51JMP Securities
RatingMarket Outperform unchanged
Price target$60 unchanged
ATRCAtriCure, Inc.$61.51Needham
RatingBuy unchanged
Price target$51 → $44 −13.7% · −$7
Wednesday · Apr 2, 2025
ATRCAtriCure, Inc.$61.51Citizens Capital Markets
RatingMarket Outperform unchanged
Price target$60 unchanged
Friday · Mar 28, 2025
ATRCAtriCure, Inc.$61.51Canaccord Genuity
RatingBuy unchanged
Price target$66 → $52 −21.2% · −$14
Thursday · Mar 27, 2025
ATRCAtriCure, Inc.$61.51BTIG
RatingBuy unchanged
Price target$57 → $58 +1.8% · +$1
ATRCAtriCure, Inc.$61.51JP Morgan
RatingOverweight unchanged
Price target$51 → $46 −9.8% · −$5
ATRCAtriCure, Inc.$61.51Needham
RatingBuy unchanged
Price target$51 unchanged
Friday · Mar 21, 2025
ATRCAtriCure, Inc.$61.51Needham
RatingBuy unchanged
Price target$51 unchanged
Thursday · Feb 13, 2025
ATRCAtriCure, Inc.$61.51BTIG
RatingBuy unchanged
Price target$53 → $57 +7.5% · +$4
ATRCAtriCure, Inc.$61.51Oppenheimer
RatingOutperform unchanged
Price target$36 → $45 +25.0% · +$9
ATRCAtriCure, Inc.$61.51Piper Sandler
RatingOverweight unchanged
Price target$40 → $50 +25.0% · +$10
Source: Yahoo Finance analyst upgrades and downgrades (firm, rating, price target), refreshed after each US market close for the stocks SURVYR. covers. Yahoo doesn't name the individual analyst. "Price at note" is that day's closing price from our daily price history (the prior close when the note came before the open); the upside or downside is the distance from it to the new target. Details opens the matching news story when we have one, otherwise the stock's Yahoo Finance analysis page. Ratings and targets belong to the firms named; SURVYR. doesn't rate stocks, set targets or give advice. Not investment advice · Important disclosures
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
SURVYR
Free to use. No card, no ads, no auto-renew.
Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026